From Surf Wiki (app.surf) — the open knowledge base
Forodesine
Chemical compound
Chemical compound
| Field | Value | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| type | ||||||||||||||||
| IUPAC_name | 7-[(2*S*,3*S*,4*R*,5*R*)-3,4-Dihydroxy-5-(hydroxymethyl)-2-pyrrolidinyl]-1,5-dihydropyrrolo[2,3-*e*]pyrimidin-4-one | |||||||||||||||
| image | Immucillin H.svg | |||||||||||||||
| image_class | skin-invert-image | |||||||||||||||
| tradename | Mundesine and Fodosine | |||||||||||||||
| licence_CA | ||||||||||||||||
| licence_EU | ||||||||||||||||
| DailyMedID | ||||||||||||||||
| licence_US | ||||||||||||||||
| pregnancy_AU | ||||||||||||||||
| pregnancy_US | ||||||||||||||||
| routes_of_administration | oral | |||||||||||||||
| legal_AU | ||||||||||||||||
| legal_BR | ||||||||||||||||
| legal_CA | ||||||||||||||||
| legal_DE | ||||||||||||||||
| legal_NZ | ||||||||||||||||
| legal_UK | ||||||||||||||||
| legal_US | ||||||||||||||||
| legal_UN | ||||||||||||||||
| legal_status | ||||||||||||||||
| CAS_number | 209799-67-7 | |||||||||||||||
| ATC_prefix | ||||||||||||||||
| PubChem | 444499 | |||||||||||||||
| ChemSpiderID | 392417 | |||||||||||||||
| UNII | 426X066ELK | |||||||||||||||
| KEGG | D06596 | |||||||||||||||
| ChEMBL | 218291 | |||||||||||||||
| C | 11 | H=14 | Ag= | Al= | As= | Au= | B= | Bi= | Br= | Ca= | Cl= | Co= | F= | Fe= | Gd= | I= |
| K | Li= | Mg= | Mn= | N=4 | Na= | O=4 | P= | Pt= | S= | Sb= | Se= | Sr= | Tc= | Zn= | charge= | |
| SMILES | C1=C(C2=C(N1)C(=O)NC=N2)[C@H]3[C@@H]([C@@H](C@HCO)O)O | |||||||||||||||
| StdInChI | 1S/C11H14N4O4/c16-2-5-9(17)10(18)7(15-5)4-1-12-8-6(4)13-3-14-11(8)19/h1,3,5,7,9-10,12,15-18H,2H2,(H,13,14,19)/t5-,7+,9-,10+/m1/s1 | |||||||||||||||
| StdInChI2 | 1/C11H14N4O4/c16-2-5-9(17)10(18)7(15-5)4-1-12-8-6(4)13-3-14-11(8)19/h1,3,5,7,9-10,12,15-18H,2H2,(H,13,14,19)/t5-,7+,9-,10+/m1/s1 | |||||||||||||||
| StdInChIKey | IWKXDMQDITUYRK-KUBHLMPHBW |
| Drugs.com = | elimination_half-life =
Forodesine (INN; also known as Immucillin H; trade names Mundesine and Fodosine) is a transition-state analog inhibitor of purine nucleoside phosphorylase studied for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and for treatment of B-cell acute lymphocytic leukemia (B-ALL).
Forodesine was originally discovered by Vern Schramm's laboratory at the Albert Einstein College of Medicine in New York and Industrial Research Limited in New Zealand.
Forodesine is being developed by BioCryst Pharmaceuticals. , it is currently in phase II clinical trials..
In 2006, BioCryst entered into a licensing agreement with Mundipharma International Holdings Limited to develop and commercialize forodesine in markets across Europe, Asia, and Australasia for use in oncology.
In April 2017, forodesine was approved in Japan for the treatment of relapsed/refractory peripheral T-cell lymphoma.
References
References
- (April 2001). "Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes". Proceedings of the National Academy of Sciences of the United States of America.
- "Complete list of clinical trials for forodesine (BCX-1777) (ClinicalTrials.gov)".
- (January 16, 2007). "Biocryst Initiates Pivotal Fodosine Phase IIb Clinical Trial In Patients With Relapsed/Refractory T-Lymphoblastic Leukemia/Lymphoma".
- (April 3, 2017). "BioCryst Announces Mundipharma Receives Approval for Mundesine in Japan".
- (2018). "Forodesine in the treatment of relapsed/refractory peripheral T-cell lymphoma: an evidence-based review". OncoTargets and Therapy.
This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.
Ask Mako anything about Forodesine — get instant answers, deeper analysis, and related topics.
Research with MakoFree with your Surf account
Create a free account to save articles, ask Mako questions, and organize your research.
Sign up freeThis content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.
Report